Background
While two-dose vaccination using modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine has been shown to be effective in preventing Mpox among at-risk populations, data on the short-term durability of serological responses are scarce.
Methods
This prospective study enrolled participants planning to undergo 2-dose MVA-BN vaccination or having natural infection to investigate the serological responses after vaccination or infection. Blood samples were collected for determinations of anti-A29 and anti-H3L IgG. We randomly selected 40 participants who had undergone 2-dose vaccination, including 25 people with HIV (PWH) and 15 people without HIV (PWoH), who had completed one-year follow-up with confirmation of seroconversion for at least one of the IgG to determine the neutralizing ability with the use of a plaque reduction neutralizing test (PRNT).
Results
441 participants who had completed 2-dose MVA-BN vaccination were included, including 284 PWH and 157 PWoH. Among PWH, PWoH, and individuals with prior smallpox vaccination, the seroconversion rate for anti-A29 after the second dose of vaccination was 18.2% and 61.2%, 10.9%, respectively, and that for anti-H3L IgG was 65.0%, and 51.6% and 90.6%, respectively. Twelve (18.8%) of 64 and 41 (19.4%) of 211 participants seroreverted for anti-A29 and anti-H3L IgG, respectively, after a 7-month observation. Factors associated with loss of serologic response (seroreversion) included chronic HBV infection (aOR, 4.84; 95% CI, 1.02-23.11) and HCV seropositivity (aOR, 4.84; 95% CI, 1.02-23.11) for anti-A29 IgG, and participants with prior smallpox vaccination (OR, 0.32; 95% CI, 0.11-0.95) for anti-H3L IgG. Of the total of 150 samples examined by PRNT, 103 (68.7%) showed neutralizing ability. The titer of anti-H3L MPXV IgG was modestly correlated with the titer of PRNT (r = 0.38, p < 0.001), while that of anti-A29 MPXV IgG showed no correlation with the titer of PRNT (p=0.14). Of the 16 participants with recent Mpox, 3 (30.0%) and 9 (90.0%) of 10 remained seropositive for anti-A29 and anti-H3L IgG, respectively, at the end of 7 months of follow-up.
Conclusions
We found that the anti-A29 and anti-H3L antibodies waned quickly among those have undergone MVA-BN vaccination and even among those with natural infection. In addition, among those tested positive for Mpox-specific IgG, the titers of anti-H3L IgG might be a better index for predicting neutralizing ability compared with the titers of anti-A29 IgG.
Table or Figure
![]()